Arkin Bio Launches $100M Early-Stage Fund
Arkin Capital announced today the closing of Arkin Bio Ventures III, a $100 million fund to invest in advanced pre-clinical and early clinical-stage biotech companies. The fund, backed by institutional investors including Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, targets 10–12 companies in oncology, immunology, inflammation, rare diseases and other high unmet-need areas. Led by Dr. Pini Orbach, the fund emphasizes biology-first investing and hands-on translational support to accelerate proof-of-concept.
Scoring Rationale
Official $100M fund announcement provides concrete investment signal, but limited novelty and industry-wide impact constrains broader significance.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
